About
Monoclonal Antibodies for Cancer Treatment
cCAM Biotherapeutics is a preclinical-stage company focused on the discovery and development of novel immunotherapies to treat cancer. The company's lead product, CM-24, is a phase 1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1, leading to an enhanced anti-tumor immune response of T and NK cells. cCAM Biotherapeutics' activity has been fully integrated into Merck & Co. Inc.
Identity
| Name | cCAM Biotherapeutics |
|---|---|
| Slug | ccam-biotherapeutics |
| Type / kind | startup |
| Crunchbase ID | ccam-biotherapeutics |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6n6MkIDA |
Status
| Status | inactive |
|---|---|
| Status reason | Acquired (Inactive) by Merck on Jul 2015 - closed due to acquisition |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Hod HaSharon |
| HQ address | HaHarash St 34, Hod Hasharon, Israel |
Web & social
| https://www.linkedin.com/company/6015961 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
therapeuticscancerpharmaceuticalsimmunologytreatmentspharma-companies
Funding
| Total raised | $8.0M |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}